Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, April 10, 2019

Clot-Picking in Stroke Scores Meta-Analysis Win

The measurement of success is wrong. 100% recovery is the goal.  You are assuming that the tyranny of low expectations is ok with stroke survivors. It isn't. You have a hell of lot more work to do to get to 100% recovery. WHEN THE HELL ARE YOU GOING TO ADDRESS THAT GOAL?

Clot-Picking in Stroke Scores Meta-Analysis Win

No reduction in intracranial hemorrhage risks, however, compared with standard medical therapy

  • by Staff Writer, MedPage Today
Endovascular thrombectomy improved survival outcomes in the first 90 days following acute ischemic stroke, but had little effect on intracranial hemorrhage when compared with standard medical therapy, a meta-analysis found.
Compared with medical therapy, endovascular thrombectomy significantly lowered the risk of 90-day mortality by 3.7% (18.7% vs 15.0%; P=0.03), reported Georg Wolff, MD, of Heinrich-Heine-University in Germany, and colleagues in JAMA Neurology.
However, the risk of intracranial hemorrhage did not differ for patients treated with medical therapy versus those who had endovascular thrombectomy (4.0% vs 4.2%; P=0.65), the researchers found.
The 2018 American Stroke Association (ASA)/American Heart Association (AHA) guidelines for acute ischemic stroke suggest that endovascular thrombectomy benefits functional outcomes, the investigators noted.
There are a number of "striking" similarities between the management of myocardial infarction and acute ischemic stroke. For both events, intravenous thrombolysis was established first to better clinical outcomes, and later was considered inferior to interventional methods of primary percutaneous coronary intervention. Unlike for intravenous thrombolysis for treatment of myocardial infarction, however, improved survival following acute ischemic stroke was not evident in either short-term or long-term follow-up, the researchers emphasized.
"We cannot help but see the parallels: endovascular strategies may well turn out to be as successful in AIS [acute ischemic stroke] as in myocardial infarction," the researchers wrote.
The meta-analysis highlighted the benefit in stroke mortality when using this therapy in appropriately selected patients, noted Shreyansh Shah, MD, of Duke University Health System in Durham, North Carolina, who was not involved in the study. "Now the next step the stroke community needs to take is to improve access to this life-saving therapy. Only then would we be able to realize the potential of this therapy -- that is, to see a reduction in stroke mortality at the population level," Shah told MedPage Today.
Wolff's group reviewed 10 trials that included 2,313 patients. Singular study information was incorporated using a random-effects model to calculate summary statistics of risk ratios along with 95% confidence intervals and the Cochran-Mantel-Haenszel method. Information abstractions were done by two independent investigators and verified by four others.
Trials were excluded from the meta-analysis for using endovascular thrombectomy devices in only a minority of patients and having the wrong comparators. Inclusion criteria were ASA/AHA guidelines-related randomized clinical trials evaluating medical therapy compared with endovascular thrombectomy.
Other data showed similar trends in late-window trials as the relative risk was 0.76 (P =0.38) and early-window trials only as the relative risk was 0.83 (P =0.06), the team noted.
Study limitations, Wolff and co-authors noted, included bias due to trials ending prematurely and protocol heterogeneity.
Wolff was supported by the Forschungskommission of the Medical Faculty of the Heinrich-Heine-University Düsseldorf.

No comments:

Post a Comment